Data derived from the TCGA (The Cancer Genome Atlas) platform (https://www.cbioportal.org) strengthen our interpretation for perturbed (compromised) aldehyde reductase activities in advanced metastatic UBC disease, with 16% and 7% of the examined muscle-invasive UBC patients (Bladder Cancer, Cell 2017, z: 1.5) exhibiting deregulated expression/activity of the AKR1A1 and AKR1B1 enzymes, respectively, and 2.67% of them bearing low mRNA levels of the AKR1A1 gene (https://www.cbioportal.org). The gene discussed is AKR1B1; the disease is urinary bladder cancer.